



**State of New Jersey**  
OFFICE OF THE ATTORNEY GENERAL  
DEPARTMENT OF LAW AND PUBLIC SAFETY  
PO BOX 080  
TRENTON NJ 08625-0080

JON S. CORZINE  
*Governor*

ANNE MINGRAM  
*Attorney General*

April 1, 2008

Honorable Patrick J. Diegnan, Jr.  
Assemblyman, District 18  
908 Oak Tree Ave, Unit P  
South Plainfield, New Jersey 07080

Dear Assemblyman Diegnan:

Thank you for your recent correspondence inquiring on what action this Office is taking regarding allegations that various pharmaceutical companies have misrepresented the safety and effectiveness of anti-psychotic drugs.

New Jersey is part of a multi-State working group investigating the sale of Zyprexa by Eli Lilly & Co. There are approximately 30 states involved in the investigation which focuses on three primary issues: (1) Eli Lilly's promotion of Zyprexa for uses that were not FDA approved, including promotion for use in the elderly and in children; (2) Eli Lilly's alleged failure to disclose risks associated with Zyprexa, namely diabetes and weight gain; and (3) any misrepresentations Eli Lilly made regarding advantages Zyprexa may have offered over other anti-psychotic medications. As you may be aware, last week Eli Lilly agreed to settle a lawsuit filed by the state of Alaska claiming that Zyprexa caused patients to develop diabetes.

Please be assured that this Office remains committed to taking appropriate action when we learn of allegations of misrepresentations related to the safety and effectiveness of pharmaceuticals.

Thank you for contacting me to bring your interest in this matter to my attention.

Sincerely,

Ann Mingram  
Attorney General

